ArticleDevelopment (Cambridge, England)2025
Twinfilin modulates tissue contractility through uncapping of capping protein in C. elegans.
Article in Development (Cambridge, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The actin cytoskeleton is dynamically remodeled by conserved regulators to control cell and tissue mechanics. Although many of these proteins are well studied, their roles in driving tissue-specific contractility remains unclear. Twinfilin, an actin uncapper and depolymerase, has not previously been linked to tissue contractility. Here, we show that the sole twinfilin ortholog in C. elegans, TWF-2, modulates actomyosin contractility in the spermatheca. TWF-2 localizes to the spermathecal cortex through interactions with α-spectrin (SPC-1) and β-spectrin (UNC-70). In vitro, TWF-2 inhibits depolymerization of ADP-actin filaments and modestly promotes depolymerization of ADP-Pi-actin filaments, while also rapidly displacing capping protein (CAP-1 and CAP-2) from filament barbed ends. In vivo, loss of TWF-2 alone does not produce an obvious phenotype, but simultaneous loss of TWF-2 partially rescues the embryonic lethality caused by CAP-1 depletion. Likewise, loss of the contractility regulator SPV-1 results in elevated F-actin and phosphorylated myosin, leading to hypercontractility; this phenotype is suppressed by removing TWF-2, which lowers F-actin levels without affecting myosin or its phosphorylation. These findings demonstrate that TWF-2 modulates actin dynamics in a tissue-specific manner. This work provides the first in vivo evidence that twinfilin modulates contractility and reveals how its interactions with capping protein and spectrins help maintain balanced actomyosin levels in the spermatheca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.